Literature DB >> 21200180

Antimicrobial stewardship: bridging the gap between quality care and cost.

Debra A Goff1.   

Abstract

PURPOSE OF REVIEW: Antibiotic resistance continues to rise, whereas development of new agents to counter it has slowed. A heightened need exists to maintain the effectiveness of currently available agents. This review focuses on the need for better antimicrobial stewardship, expected benefits of well designed antimicrobial stewardship programs (ASPs), and provides suggestions for development of an effective ASP. RECENT
FINDINGS: Healthcare-associated infections (HAIs) are a significant cause of poor treatment outcomes and elevated healthcare and societal costs worldwide. HAIs are often caused by antibiotic-resistant pathogens; overuse of antibiotics has been linked with antibiotic resistance. Benefits of improved antimicrobial stewardship include reduced emergence of antibiotic resistance, limitation of drug-related adverse events, minimization of other consequences of antibiotic use (e.g., superinfection), and reduction of societal and healthcare-related costs. In 2007, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) provided guidelines for the development of institutional programs to enhance antimicrobial stewardship. Experiences at The Ohio State University Medical Center (OSUMC) reinforce this message, while providing specific examples of ways to optimize ASP development and implementation. The focus of an ASP should be on improving quality of care, reducing drug resistance, and cost savings. When implementing an ASP, it is important to identify those most likely to resist the ASP, understand their concerns, and develop easy-to-understand messages that address these concerns and highlight the benefits of the proposed changes. Antibiograms play a key role in identifying local and interdepartmental trends in antibiotic susceptibility or resistance. These data are important not only in devising best-treatment practices for the institution, but also in evaluating the impact of a recently implemented ASP. Other measures of the impact of an ASP should include patient outcomes and overall costs or savings.
SUMMARY: Better antimicrobial stewardship is needed to limit the emergence of antibiotic resistance, prolong the effectiveness of currently available agents, improve patient outcomes, and reduce healthcare and societal costs associated with HAIs. Guidelines from the IDSA/SHEA and experiences at OSUMC provide examples of how best to develop an institutional ASP to accomplish these goals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21200180     DOI: 10.1097/01.qco.0000393484.17894.05

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  25 in total

1.  Selection of hospital antimicrobial prescribing quality indicators: a consensus among German antibiotic stewardship (ABS) networkers.

Authors:  J Thern; K de With; R Strauss; M Steib-Bauert; N Weber; W V Kern
Journal:  Infection       Date:  2013-12-11       Impact factor: 3.553

2.  The automated clinical microbiology laboratory: fact or fantasy?

Authors:  Nathan A Ledeboer; Steven D Dallas
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

3.  The determinants of antimicrobial prescribing among hospital doctors in England: a framework to inform tailored stewardship interventions.

Authors:  Hazel M Parker; Karen Mattick
Journal:  Br J Clin Pharmacol       Date:  2016-05-18       Impact factor: 4.335

4.  Can a collaborative subspecialty antimicrobial stewardship intervention have lasting effects?

Authors:  Kaushal B Shah; Ramzy H Rimawi; Mark A Mazer; Paul P Cook
Journal:  Infection       Date:  2017-07-19       Impact factor: 3.553

5.  Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms.

Authors:  Matthew J Neidell; Bevin Cohen; Yoko Furuya; Jennifer Hill; Christie Y Jeon; Sherry Glied; Elaine L Larson
Journal:  Clin Infect Dis       Date:  2012-06-14       Impact factor: 9.079

6.  Adherence to clinical practice guidelines for the management of Clostridium difficile infection in Japan: a multicenter retrospective study.

Authors:  K Kobayashi; N Sekiya; Y Ainoda; H Kurai; A Imamura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-02       Impact factor: 3.267

7.  Bacterial susceptibility patterns in patients with spinal cord injury and disorder (SCI/D): an opportunity for customized stewardship tools.

Authors:  K J Suda; U C Patel; R Sabzwari; L Cao; S Ramanathan; J N Hill; C T Evans
Journal:  Spinal Cord       Date:  2016-03-22       Impact factor: 2.772

8.  Clostridium difficile-associated disease: adherence with current guidelines at a tertiary medical center.

Authors:  Bryan F Curtin; Yousef Zarbalian; Mark H Flasar; Erik von Rosenvinge
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

9.  Clinical course and complications following diagnostic bronchoalveolar lavage in critically ill mechanically ventilated patients.

Authors:  R M Schnabel; K van der Velden; A Osinski; G Rohde; P M H J Roekaerts; D C J J Bergmans
Journal:  BMC Pulm Med       Date:  2015-09-29       Impact factor: 3.317

10.  Urinary tract infection diagnosis and response to therapy in long-term care: A prospective observational study.

Authors:  Peter Daley; Carla Penney; Susan Wakeham; Glenda Compton; Aaron McKim; Judy O'Keefe; Brendan Barrett; Lindsay Nicolle
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 May-Jun       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.